Cyclerion Therapeutics (CYCN) Equity Average (2018 - 2025)

Cyclerion Therapeutics' Equity Average history runs 8 years deep, the most recent figure standing at $9.3 million for Q4 2025.

• In Q4 2025, Equity Average rose 9.24% year-over-year to $9.3 million; the TTM figure through Dec 2025 stood at $9.3 million (up 9.24% YoY), while the FY2025 annual figure was $9.0 million, down 10.94% from the prior year.
• Equity Average was $9.3 million for Q4 2025 at Cyclerion Therapeutics, up from $9.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $60.8 million in Q3 2021 to a low of $4.5 million in Q2 2023.
• Historically, Equity Average has averaged $21.9 million across 5 years, with a median of $10.0 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Equity Average tumbled 85.46% in 2023, then soared 106.13% in 2024.
• A 5-year view of Equity Average shows it stood at $52.3 million in 2021, then sank by 74.22% to $13.5 million in 2022, then fell by 10.44% to $12.1 million in 2023, then declined by 29.44% to $8.5 million in 2024, then climbed by 9.24% to $9.3 million in 2025.
• The last three Equity Average figures came in at $9.3 million (Q4 2025), $9.1 million (Q3 2025), and $8.7 million (Q2 2025), per Business Quant data.